OSR Health Company Description
OSR Health, Inc., a healthcare holding company, develops a portfolio of therapies and healthcare solutions in the United States, Europe, and Korea.
The company develops immunotherapy products, including VXM01, an immuno-oncology candidate for glioblastoma completed phase 2 clinical trial, as well as preclinical stage products, such as VXM04 to treat mesothelin; VXM06 for the treatment of Wilms Tumor Protein (WT1); VXM08 for Carcinoembryonic antigen (CEA); and VXM10 for PD-L1.
It is also developing design-augmented (DA) biologics comprising DRT-102, a clinical-stage asset for spinal fusion; and DRT-101, a pre-clinical stage asset for osteoarthritis.
In addition, the company distributes neurovascular intervention medical device and systems. The company was formerly known as OSR Holdings, Inc. and changed its name to OSR Health, Inc. in June 2026.
OSR Health, Inc. was incorporated in 2020 and is based in Bellevue, Washington.
| Country | United States |
| Founded | 2020 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 22 |
| CEO | Kuk Hwang |
Contact Details
Address: 10900 NE 4th Street Bellevue, Washington 98004 United States | |
| Phone | 425 635 7700 |
| Website | osr-holdings.com |
Stock Details
| Ticker Symbol | OSRH |
| Exchange | OTCMKTS |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| ISIN Number | US68840D1028 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Senyon Choe | Founder and Chief Executive Officer of Darnatein |
| Chankyu Park | Chief Executive Officer of RMC |
| Kuk Hyoun Hwang | Chairman and Chief Executive Officer |
| Gihyoun Bang | Chief Financial Officer |
| Dr. Constance Hofer | Chief Scientific Officer |
| Jun Chul Whang | Chief Legal Officer, Secretary and Director |
| Yeiseok Kim | Chief Operating Officer |
| Tim Smith | Corporate Secretary and Global IR |